Using X-linked clonal analysis, mechanism of action of alltrans retinoic acid (ATRA) was sought in a 16-year-old female with relapsed clonally evolved acute promyelocytic leukemia (APL), who achieved complete remission. On ATRA, metamorphosis of peripheral blood leukemic promyelocytes to mature neutrophils was observed, despite the persistence of t(15;17) in 100% of bone marrow metaphases. DNA was extracted from fractionated serial blood specimens, collected at diagnosis, in first complete remission (CR), relapse, and during ATRA treatment. Using a phosphoglycerokinase (PGK) probe, the patient was heterozygous for both Bgll and Bst XI PGK polymorphisms. Methylation analysis showed monoclonal leukemic promyelocytes with a polyclonal first CR achieved by standard chemotherapy. Subsequent exami-
A tutes 5% to 15% of cases of acute nonlymphocytic leukemias (ANLL).' The disease is morphologically distinguished by the presence of hypergranular promyelocytes, with or without multiple Auer rods and clinically associated with coagulopathy, often exacerbated by treatment.' A unique cytogenetic translocation, t( 15;17), is present in the majority of cases3 Molecular characterization of chromosome 17 has identified a cluster region of breakpoints within the retinoic acid receptor-a gene (RAR-CX).~ The rearrangement produces a fusion gene product to the my1 locus on chromosome 15 that transcribes to an abnormal fusion messenger RNA (mRNA)
Although standard intensive chemotherapy can achieve complete remission (CR) in 60% to 80% of cases, induction treatment is associated with significant mortality, usually due to hemorrhage.' Recent therapeutic approaches have identified the isomer all-trans retinoic acid (ATRA) to be a potential differentiating agent in this leukemia.'^^ Clinically, ATRA has proved highly successful in achieving CR in the majority of patients with relapsedlresistant disease. ' ATRA treatment has been shown to induce differentiation in vitro by morphologic, immunologic, cytogenetic, and, recently, molecular techniques of premature chromo-nation, in relapse, of granulocytes appearing during ATRA treatment showed these to be monoclonal, proving these were derived from the neoplastic clone. The X-linked clonal analysis methodology has provided in vivo evidence of cellular differentiation as the mechanism of action of ATRA. Parallel studies of cytogenetic and clonal analysis showed a regression of the t(15; 17) cytogenetic abnormality and return of a polyclonal PGK methylation pattern in 5 weeks, indicating a repopulation of marrow by normal stem cells. As standard cytogenetic techniques are inappropriate for nondividing cells, X-linked clonal analysis provides a marker system to allow insight into mechanism of drug action in malignant hematologic disease. 0 1992 by The American Society of Hematology.
some condensation and in situ hybridization.','' These techniques depend on specific markers to differentiate the abnormal from the normal mature cell. We report the use of X-linked clonal analysis on a patient with relapsed, clonally evolved APL as a methodology to determine the origin of the mature granulocytes in vivo that appear after ATRA therapy and hence the mechanism of action of ATRA treatment. Parallel studies of cytogenetic and clonal analysis indicated a return of a polyclonal methylation pattern in 5 weeks, indicating a repopulation of marrow by normal stem cells. This report also demonstrates the usefulness of ATRA therapy in relapsed APL exhibiting clonal evolution. Induction chemotherapy with Cytarabine (100 mg/m2/d) by continuous infusion for 7 days, Daunorubicin (50 mg/m2 intravenously [IVJ) on days 1, 2, and 3, and Etoposide (75 g/m2 IV) on days 1 through to 7, was commenced. Postinduction marrow examinations showed CR without a phase of marrow hypocellularity. This was followed by consolidation and maintenance therapy.
PATIENTS AND METHODS

Patient
The patient relapsed 1 year later while on maintenance treatment. Cytogenetics analysis confirmed the recurrence of the t(15;17) clone present alone in 30% of metaphases. A coexistent abnormality, 46,XX,t( 15;17)(q22q12),-2, +der(2)t(2;?)(p25;?), was present in 70% of cells.
Initial efforts to obtain ATRA for reinduction proved fruitless and the patient was commenced on high-dose Cytarabine (3 g/m2 on days 1 through 5) and Amsacrine (200 mglm2 on days 1 through 3). By day 13 of this therapy, leukemic progression was noted with reappearance of circulating promyelocytes and recrudescence of coagulopathy (Table 1) . ATRA, obtained from Prof M.E. Huang (Shanghai, China), was commenced (day 0) at 45 mg/m2/d. The coagulopathy resolved within the first week. Hydroxyurea was introduced at 2 g per day for 3 days on day5 to moderate hyperleucocytosis. The patient entered complete cytogenetic remission and subsequently underwent allogeneic BM transplant from an HLAmatched sibling and is well and free of leukemia 7 months later.
Cytogenetic studies were performed on either BM or peripheral blood (PB). Cultures were set up without mitogens for overnight incubation and for 48-hour fluorodeoxyuridine synchronization." G-banding was performed using a modified Seabright method and karyotyped according to the ISCN recommendations.'*."
Serial PB specimens were separated into polymorphonuclear (PMN) and mononuclear (MN) fractions by Ficoll-Hypaque centrifugation. Fraction purity was assessed by Giemsa staining, with granulocytes constituting greater than 90% of cells in the PMN fraction. High molecular weight DNA was extracted from the fractions by methods previously de~cribed.'~ Restriction enzyme Bgl I was used to assess heterozygosity and, thus, interpretability for clonal analysis.15 Full methylation analysis used 20 pg of DNA digested with restriction enzymes Pst I (10 U/pg) and Bst XI (8 U/pg). Half the reaction was subsequently digested with Hpa I1 (5 U/pg). Samples were transferred to nylon membranes (Hybond N; Amersham, International, Buckinghamshire, UK) after size fractionation on a 1.5% agarose All restriction enzymes (from BoehringerMannheim, Mannheim, Germany) were used according to manufacturers recommendation. The pSPT/PGK EcoRIIBumHI 0.8-kb insert, labeled ('*-dCTP) by the oligo-labeling method, was used to probe membranes under conditions previously des~ribed.'~.'~ Membranes were exposed to X-ray film (Curk, Agfa-Gevaert, Mortsel, Germany) in X-ray cassettes (Kodak X-Omatic, New York, NY)
with intensifying screens at -80°C.
RESULTS
Response to ATRA was rapid with a steady decrease in PB promyelocytes, increase in mature neutrophils, and improvement in coagulopathy (Table 1 and Fig 1) . Hyperleucocytosis was easily managed with hydroxyurea with an immediate decrease in WBC noted.
Within 1 week of ATRA treatment, the promyelocyte numbers reduced with the appearance of transitional "myeloid" cells and eventually mature granulocytes (Fig 1) . Transitional cells had dysmorphic features of atypical nuclei and granule development. BM performed at day 7 showed persistent hypercellularity, although significant maturation of the myeloid cells was observed.
Initial BM cytogenetics at first presentation identified the standard t(15;17)(q22;q12) in 100% of Clinical response.
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cells. A complete cytogenetic remission was obtained postchemotherapy.
On relapse, cytogenetics disclosed two abnormal cell lines, the standard 46,XX,t( 15;17)(q22;q12), and a second, 46,XX,t(15;17)(q22;q12), -2,+der(2)t(2;?)(p25;?). Cytogenetically, 15% of the 20 metaphases demonstrated the stanaard translocation, and 85% showed the evolved clone at day 0 on ATRA (Table 2) . At 1 week post-ATRA treatment, only the evolved clone was present from eight metaphases. Normal diploid metaphases appeared at day 14, with three cell lines present, the normal predominant, at day 28. Complete cytogenetic remission was apparent by day 35.
The restriction fragment length poiymorphism (RFLP) with Bgl I enzyme was identified in the patients DNA showing two bands, 12 and 5 kb, with the X-linked phosphoglycerokinase (PGK) probe (results not shown). The patient's DNA was also heterozygous for the RFLP restriction enzyme, Bst XI, which has strong linkage equilibrium with the Bgl I RFLP.'' The patient's mononuclear cell (lymphocytes) DNA (Fig 2, Lane la) demonstrated the RFLP with Bst XI and Pst I, distinguishing the Molecular. For personal use only. on September 14, 2017. by guest www.bloodjournal.org From two X chromosomes. Subsequent methylation sensitive restriction enzyme (MSRE) digestion with Hpa 11, identified a polyclonal pattern, with a 50% reduction in intensity of both bands (Fig 2, lane lb) . DNA extracted from the initial abnormal promyelocytes containing the unique translocation, t( 15;17)(q22;q12), showed a total loss of a single band after MSRE digestion (Fig 2, lane 2b) . From the X-linked methylation methodology, this confirms that the X-chromosome defined by the 0.9-kb band was entirely in the active form, proving these abnormal cells to be monoclonal. Relapsed promyelocytes demonstrating the additional abnormal -2,+der(2)t(z;?)(p25;?) clone to the standard 46,XX,t( 15;17) translocation had the same pattern as the original abnormal promyelocytes, indicating that these were again monoclonal (results not shown). DNA extracted from the PMN fraction 7 days after ATRA treatment (D7), also displayed a single band after MSRE digestion, confirming a monoclonal pattern identical to that of the abnormal promyelocytes (Fig 2, lane 3b) . The PGK analysis of the granulocytes at day 35 of ATRA treatment showed a polyclonal pattern with the presence of both bands (1.05 and 0.9 kb) after MSRE digestion (Fig 2, lane 4b) . Hematologic and cytogenetic remission correlated with a return to a polyclonal methylation pattern. X-linked clonal analysis provides an alternative methodology to investigate clonal origin of mature cells that appear aftcr therapy." Analysis of the leukcmic promyelocytes at presentation identified a monoclonal pattern consistent with a single cell origin. This result highlights the use of this extrinsic methodology to confirm monoclonality of the cells that already have an intrinsic cytogenetic clonal marker.
Analysis of granulocytes collected at 1 and 3 months postinitial induction chemotherapy demonstrated a polyclonal pattern in the presence of a hypercellular marrow. Differentiation has been postulated as the mechanism of hypercellular remission in APL and, indeed, monoclonal granulopoietic remissions have been previously noted in this disease.'.'' Although it is possible that a monoclonal phase of granulopoeisis was missed in this patient, our results suggest that hypercellular remissions in APL are polyclonal with the elimination of the abnormal clone and regeneration of normal stem cells.
The promyelocytes at relapse, demonstrating the additional abnormal clone to the standard cytogenetic abnormality, were again monoclonal with the same pattern as the promyelocytes at diagnosis. This clone is thus likely to be derived from the original clone and does not represent emergence of a coexistent initial population. Transitional peripheral myeloid cells that appeared after ATRA treatment coincided with the persistence of the abnormal clone For personal use only. on September 14, 2017. by guest www.bloodjournal.org From in 100% of the eight BM metaphases studied. Subsequent clonal analysis of this PMN fraction showed an identical monoclonal pattern to the promyelocytes. This confirms in vivo the differentiative action of ATRA. Interestingly, ATRA was able to differentiate the abnormal promyelocytes despite clonal evolution.
Five weeks after treatment with ATRA the patient entered a complete cytogenetic remission. Serial clonal
